AWM Investment Company Inc. Has $2.21 Million Stock Holdings in OptimizeRx Corp. $OPRX

Key Points

• AWM Investment Company Inc. increased its holdings in OptimizeRx Corp. by 18.6%, acquiring an additional 40,000 shares and now owning approximately 1.38% of the company worth $2.2 million.
• As of the latest reporting, institutional investors collectively own 76.47% of OptimizeRx stock, indicating strong institutional interest in the company.
• OptimizeRx shares recently received multiple "buy" ratings from analysts, with Stifel Nicolaus raising its price target to $18.00.

AWM Investment Company Inc. raised its holdings in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) by 18.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 255,421 shares of the company's stock after acquiring an additional 40,000 shares during the quarter. AWM Investment Company Inc. owned 1.38% of OptimizeRx worth $2,212,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Whetstone Capital Advisors LLC raised its holdings in OptimizeRx by 11.7% during the 1st quarter. Whetstone Capital Advisors LLC now owns 1,508,303 shares of the company's stock worth $13,062,000 after buying an additional 157,880 shares during the period. Blair William & Co. IL raised its holdings in OptimizeRx by 4.9% during the 1st quarter. Blair William & Co. IL now owns 631,031 shares of the company's stock worth $5,465,000 after buying an additional 29,648 shares during the period. Dimensional Fund Advisors LP raised its holdings in OptimizeRx by 9.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company's stock worth $2,159,000 after buying an additional 39,740 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in OptimizeRx by 12.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 295,717 shares of the company's stock worth $1,437,000 after buying an additional 32,062 shares during the period. Finally, Invesco Ltd. acquired a new stake in OptimizeRx during the 1st quarter worth about $2,542,000. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Stock Down 3.8%

NASDAQ:OPRX traded down $0.71 during mid-day trading on Monday, reaching $18.11. The stock had a trading volume of 129,628 shares, compared to its average volume of 380,253. The business's 50 day moving average is $14.91 and its 200 day moving average is $11.48. OptimizeRx Corp. has a fifty-two week low of $3.78 and a fifty-two week high of $19.25. The stock has a market cap of $336.23 million, a P/E ratio of -33.48 and a beta of 1.20. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Roth Capital restated a "buy" rating on shares of OptimizeRx in a report on Friday, August 8th. Citigroup restated an "outperform" rating on shares of OptimizeRx in a report on Tuesday, May 13th. JMP Securities upped their target price on OptimizeRx from $14.00 to $20.00 and gave the company a "market outperform" rating in a report on Monday, August 11th. Wall Street Zen upgraded OptimizeRx from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, Stifel Nicolaus upped their target price on OptimizeRx from $16.00 to $18.00 and gave the company a "buy" rating in a report on Friday, August 8th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $11.81.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.